Date published: 2026-9-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

CHAC1 Lentiviral Activation Particles (m): sc-427280-LAC

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
  • CHAC1 Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
  • CHAC1 Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
  • Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by CHAC1 Lentiviral Activation Plasmid (m) and CHAC1 Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Chac1 promoter. One or both designs may be available
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    CHAC1 Lentiviral Activation Particles (m)

    sc-427280-LAC
    200 µl
    $455.00

    CHAC1 Lentiviral Activation Particles (m2)

    sc-427280-LAC-2
    200 µl
    $455.00

    Mouse Chac1 encodes CHAC1, a cytosolic γ-glutamyl cyclotransferase that degrades glutathione and links redox homeostasis to cellular stress responses. CHAC1 is induced downstream of the unfolded protein response, particularly the PERK–eIF2α–ATF4 branch, and can contribute to oxidative stress, altered amino acid metabolism, and regulated cell death programs. Through modulation of intracellular glutathione pools, CHAC1 influences ferroptosis susceptibility, mitochondrial stress signaling, and inflammatory transcriptional outputs. Dysregulated CHAC1 expression has been associated with contexts of ER stress and neurodegeneration, ischemic and metabolic stress, and tumor biology, making it a useful node for mechanistic studies in stress-adaptation pathways.

    CHAC1 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Chac1 upregulation across a broader range of human cell types.

    CHAC1 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Chac1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous CHAC1 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Chac1 genomic locus and regulatory architecture.

    The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.